James Donohue
Pulmonary Disease · Chapel Hill, NCNPI 1740353556
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.4%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 22.4%. Reporting peaked in 2019 at $136,140 and has fallen 90.0% since, to $13,654 in 2025. Among pulmonary disease clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 255 payments — averaging $1061.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mylan Specialty L.p.$61K
- GSK$60K
- Insmed, Inc.$32K
- Grifols USA, LLC$26K
- Astrazeneca UK Limited$21K
- Mylan Inc.$11K
- plus $61K from 10 others
Across 3 payments — averaging $14,200 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim International GmbH$42K
- Chiesi USA, Inc.$800
What the payments were for
- Consulting fees$111,66241%
- Speaking & faculty fees$139,20451%
- Travel & lodging$15,9896%
- Food & beverage$3,9091%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mylan Specialty L.p. | 88 | $60,717 |
| GSK | 67 | $60,192 |
| Insmed, Inc. | 19 | $31,727 |
| Grifols USA, LLC | 30 | $25,763 |
| Astrazeneca UK Limited | 15 | $20,614 |
| Mylan Inc. | 6 | $10,780 |
| UCB SA | 4 | $9,800 |
| Sanofi US Services Inc. | 3 | $9,217 |
| Chiesi USA, Inc. | 4 | $8,975 |
| Pneumrx, Inc | 2 | $7,636 |
| AstraZeneca | 2 | $6,700 |
| Viiv Healthcare Company | 2 | $6,500 |
| Merck | 8 | $6,375 |
| Boehringer Ingelheim | 3 | $4,930 |
| Grifols Shared Services North America, Inc. | 1 | $820 |
| Pfizer | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Yupelri$66,137
- TRELEGY ELLIPTA$33,007
- Prolastin-C Liquid$20,597
- NUCALA$12,904
- ANORO$11,528
- FASENRA$10,500
- BREZTRI$8,947
- PNEUMRX COILS$7,600
- Prolastin-C$5,754
- SPIRIVA$4,930
- BREZTRI AEROSPHERE$4,767
- Wixela Inhub$4,375
- Arikayce$4,000
- MK-7264$2,625
- ANORO ELLIPTA$112
How this compares
$270,764 in reported general payments places this provider in the 95th percentile of 393 pulmonary disease providers in North Carolina.
Other pulmonary disease in Chapel Hill
- Hubert FordChapel Hill$94K
- Scott DonaldsonChapel Hill$47K
- Michael KnowlesChapel Hill$36K
- Mary DanielsChapel Hill$15K
- Michael PritchettPinehurst$1.3M
- Michael WertGreensboro$412K
- Eugene BleeckerWinston Salem$357K
- Bradley IcardPinehurst$299K
- Eric MeltzerDurham$262K
- Daniel BreaultWilmington$257K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.